Annexins and membrane dynamics  by Gerke, Volker & Moss, Stephen E
 .Biochimica et Biophysica Acta 1357 1997 129–154
Review
Annexins and membrane dynamics
Volker Gerke a,), Stephen E. Moss b
a Institute for Medical Biochemistry, ZMBE, Uni˝ersity of Munster, ˝on-Esmarch-Str. 56, D-48149 Munster, Germany¨ ¨
b Department of Physiology, Uni˝ersity College London, London WC1E 6BT, UK
Received 21 November 1996; revised 18 February 1997; accepted 28 February 1997
Keywords: Calcium; Endocytosis; Exocytosis; Ion channel
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
2. Biochemical properties and three-dimensionalfolding . . . . . . . . . . . . . . . . . . . . . . . . . . 130
2.1. General biochemistry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
2.2. Molecular structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
2.3. Annexin protein ligands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
3. Annexin ion channels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
3.1. Evidence for and against the annexin ionchannels . . . . . . . . . . . . . . . . . . . . . . . . . 136
3.2. Is there a physiological annexin ion channel? . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
3.3. Annexins as ion channel regulators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
4. Gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
4.1. Annexin gene regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
4.2. Cell growthrdifferentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
5. Involvement in membrane traffic and membraneorganization . . . . . . . . . . . . . . . . . . . . . 141
5.1. Intracellular localization and potential targetmembranes for individual annexins . . . . . . . 142
5.2. Annexins in exocytosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
5.3. Annexins in endocytosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
5.4. Annexins in membrane organization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
6. Conclusions and outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
) Corresponding author. Fax: q49 251 836748.
0167-4889r97r$17.00 Copyright q 1997 Elsevier Science B.V. All rights reserved.
 .PII S0167-4889 97 00038-4
( )V. Gerke, S.E. MossrBiochimica et Biophysica Acta 1357 1997 129–154130
1. Introduction
Intracellular Ca2q signalling and Ca2q homeosta-
sis are among the central problems in cell biology
that have received major attention for a number of
decades. Fascinating and intricate signalling path-
ways and modes of regulation have emerged from
research in this area, boosting among other things our
understanding of the regulation of intracellular Ca2q
levels through specific channels and pumps located in
the plasma membrane and in the membranes of intra-
cellular organelles. Conceptually, proteins involved
directly in Ca2q signalling and Ca2q homeostasis
should be able to bind the divalent cation and consid-
erable effort has been put into the identification of
such Ca2q effector proteins. In fact, a vast number of
intracellular Ca2q binding proteins are known to
date, only a few of them, however, having a clear
function assigned to them. Among the Ca2q binding
proteins whose function still is enigmatic are the
annexins, a discrete multigene family of Ca2q bind-
ing proteins characterized by their ability to interact
Ca2q dependently with membrane phospholipids.
Properties and potential functions of annexins will be
discussed in this review which will put a particular
emphasis on recent developments and the putative
roles of annexins in cellular physiology and mem-
brane biology.
A typical annexin protein is characterized by two
distinct features: it exhibits Ca2q-dependent binding
to phospholipids, preferentially acidic phospholipids
containing one to several negative charges, and it
contains as a conserved sequence element the an-
nexin repeat, a segment of some 70 amino acids
which is repeated four or eight times in a given
member of the family. Thus, biochemical and gene
cloning approaches have led to the formulation of the
annexin characteristics and to the classification of a
given protein or gene as an annexin. Moreover, such
approaches have proven very helpful to identify an-
nexins, which were initially described in higher verte-
brates, in a larger number of other organisms ranging
from lower vertebrates to insects, nematodes and
plants. While very distinct structural and biochemical
criteria define an annexin, proteins of this multigene
family have been implicated in a wide range of
biological processes often but not always related to
membranes. These include the regulation of mem-
brane organization, membrane traffic, membrane–
cytoskeleton linkage, and ion conductance across
membranes. Based on biochemical properties dis-
played by at least some annexins, e.g. the inhibition
of phospholipase A , the inhibition of blood coagula-2
tion, and the binding to certain matrix or extracellular
components, members of the family are also pro-
posed to function as anti-inflammatory and anti-
coagulant compounds and as mediators or regulators
of certain cell–cell and cell–matrix interactions. This
diversity in putative function reflects itself in the
number of different names initially given to proteins
of the annexin family, e.g. lipocortins, chro-
mobindins, calcimedins, anticoagulant proteins, an-
chorins. The nomenclature tangle has meanwhile been
resolved with the introduction of the universal name
w xannexin 1 . Several excellent reviews of the recent
past have discussed in detail the diversities in pro-
posed functions and names and the general biochemi-
cal and structural properties of the annexins and we
recommend this literature to the interested reader
w x2–5 . The emphasis of this review, thus, does not lie
in a complete survey of the annexin literature but in
discussing some recent findings relating annexins to
certain aspects of membrane organization, membrane
traffic, and cellular physiology.
2. Biochemical properties and three-dimensional
folding
2.1. General biochemistry
The Ca2q-dependent binding of annexin to nega-
tively charged membrane phospholipids is well docu-
mented and regarded as a biochemical hallmark of
the family. A detailed comparison as to the Ca2q
affinities and phospholipid specificities of different
w xannexin is given in a recent review 5 and the
general picture emerging from this comparison is that
annexins preferentially bind to membranes containing
negatively charged phospholipid phosphatidic acid,
.phosphatidylserine, phosphatidylinositol . This pe-
ripheral membrane binding is strictly Ca2q-dependent
and is often accompanied by a Ca2q-dependent ag-
gregation of membrane surfaces, e.g. of phospholipid
vesicles. The Ca2q concentrations required by differ-
ent annexins for half-maximal membrane binding and
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lipid vesicle aggregation cover a wide range with
annexins I and II requiring the least sub-micromolar
2q .to a few micromolar Ca for half-maximal binding
2q and annexin V requiring the most Ca 10 to )100
mM Ca2q for half-maximal binding, depending on
. w xthe phospholipid and the conditions employed 5 .
Recently, this picture of a strictly ionic interaction of
annexins with acidic phospholipids has become more
complex. It was shown, for example, that annexins
can also bind to non-charged phospholipids, e.g.
phosphatidylethanolamine and phosphatidylcholine,
albeit requiring high Ca2q concentrations for such
w xinteractions 6–9 . Moreover, a direct non-ionic inter-
action between a hydrophobic amino acid side-chain
of the protein and the lipid phase of the bilayer has
2q w xbeen observed for Ca -bound annexin V 10–14 .
Finally, several annexins, e.g. annexin II, V and VI,
also appear to associate with biological membranes in
2q  .a mode not regulated by Ca see below .
The molecular mechanism underlying the vesicle
aggregation is not completely understood. It remains
possible that each annexin polypeptide contains two
spatially separated lipid binding sites and experimen-
tal support for this view has been provided, e.g., in
w xthe case of annexin I 7,15,16 . On the other hand,
there is increasing evidence that at least for some
annexins vesicle aggregation requires the self-associ-
ation of two annexin molecules bound to two sepa-
 w x.rate membranes for review see 2,5 . However, such
a scenario is likely to be different in the case of
annexins II and VI which clearly contain two distinct
lipid binding domains per physical entity. This is the
result of a duplication of the principal annexin unit
 .the annexin core domain either through cross-lin-
king via a protein ligand p11 in the case of the
.annexin II p11 complex or through gene duplica-2 2
 .tion in annexin VI, Fig. 1 . Annexin-mediated aggre-
gation of membrane vesicles, i.e. the cross-linking of
two membrane surfaces, is a prerequisite for the
membrane fusion activity displayed by annexins.
However, in a simple system consisting of membrane
vesicles, an annexin protein and Ca2q, the rate of
fusion is very slow, indicating that annexins are not
w xfusogenic proteins per se 2 . Interestingly, certain
components, in particular cis-unsaturated fatty acids,
when added to the vesicle–annexin–Ca2q mixture
can markedly increase the rate of fusion, suggesting
that annexin-mediated membrane fusion might be
Fig. 1. Structural organization of different annexins. Known
vertebrate annexins are classified according to structural charac-
teristics of their N-terminal domains. The four annexin repeats
 .eight in the case of annexin VI are schematically represented by
rectangles with a highly conserved sequence of 17 amino acid,
the endonexin fold, shown in grey. The preceding N-terminal
domains vary in length between 12 and 19 annexins III, IV, V,
.  .VIII and close to 200 residues annexin XI and show certain
structural features. In annexins I and II these include amphipathic
 .a-helices small rectangles representing binding sites for S100
 .protein ligands p11 in the case of annexin II , phosphorylation
 .  .  .sites for serine S rthreonine T and tyrosine Y specific
 .protein kinases and a glutamine Q residue at position 18 of the
annexin I chain which is the site for a transglutaminase cross-link.
In annexins VII and XI the long N-terminal domain is rich in
 .  .glycine G , tyrosine and proline P residues which have been
proposed to form a pro-beta helix. N-terminal splice variants
have been reported for different annexins, e.g. annexin XIII a
.and b which is the only annexin described so far to become
N-terminally myristoylated. See text for references.
physiologically meaningful when elevated concentra-
tions of free polyunsaturated fatty acids occur within
w xcells 2,17 . While vesicle fusion following aggrega-
tion under the above-mentioned circumstances should
be an activity principally displayed by all annexins
remarkable differences are observed when individual
members of the family are compared, e.g. the rate of
( )V. Gerke, S.E. MossrBiochimica et Biophysica Acta 1357 1997 129–154132
Ca2q-dependent fusion between phospholipid vesicles
and neutrophil plasma membrane preparations is sub-
stantially increased by annexin I but inhibited by
w xannexin V 18 . Collectively these data show that
different annexins albeit all capable of binding phos-
pholipids in a Ca2q-dependent manner display pro-
found differences in their Ca2q threshold for lipid
binding and vesicle aggregation and their ability to
catalyze fusion of membrane bilayers.
2.2. Molecular structure
The binding of annexins to the common ligands,
Ca2q and phospholipid, is mediated through a struc-
turally well-conserved domain, the annexin protein
core. This core was initially defined through its char-
acteristic resistance towards limited proteolytic treat-
w xment 19–22 . Sequence analysis, initially reported
w xfor annexins I and II 23–26 , revealed that the
characteristic annexin core comprises four tandemly
repeated segments, each 70–80 amino acids in length.
The segments, termed annexin repeats, show intra-
and intermolecular sequence homologies sequence
w x.comparisons and homology values are given in 27 .
Crystal structure analysis, initially carried out for
w xannexin V 11,28,29 and later also for annexins I, II,
w xIII, VI and XII 30–35 , described a very characteris-
tic and highly homologues folding for the different
annexin cores which most likely can serve as a
blueprint for the entire family, thus defining an an-
nexin structurally. The cores, typically some 300
residues in length, have the shape of a compact,
slightly curved disc with the four annexin repeats
forming four domains. These are arranged in a cyclic
array with repeats 1 and 4, and 2 and 3, respectively,
building tight modules stabilized through hydropho-
 w x.bic side-chain interactions for review see 36–38 .
The centre of the molecule, separating the repeat 1r4
and repeat 2r3 modules, is a hydrophilic pore pro-
posed to represent an ion conductance pathway and
thus the structural basis for the Ca2q channelling
activity displayed by some annexins in vitro for
w x .review see 39,40 ; see below for details .
In the folded molecule each annexin repeat com-
 .prises five a-helices a–e wound into a right-handed
superhelix. The helices are connected through short
loops or turns and loops extending from the more
convex side of the curved disc are involved in Ca2q
w x 2qcomplexation 41 . Two types of Ca binding sites
have been identified in annexin crystals. They have
been termed type II and type III binding sites to
distinguish them from the long-known and well-char-
acterized EF hand or ‘‘type I’’ Ca2q binding site
found in proteins like parvalbumin and troponin C
w x 2q30 . In the type II site the Ca ion coordinates to
three carbonyl oxygens of the peptide bonds located
in the loop connecting helices a and b and to the
carboxyl oxygens of an aspartate or glutamate residue
 .the so-called cap residue found in or close to the
loop connecting helices d and e of an annexin repeat.
The type III site offers only three proteinaceous
oxygen ligands for Ca2q complexation, usually one
carbonyl and two nearby carboxylate oxygens. Crys-
tallization studies and electron microscopical analy-
ses have been carried out to describe the structural
basis of annexin–monolayer interactions. These data
reveal that in the case of a four repeat annexin
 .annexin V the convex surface of the folded annexin
is orientated towards the membrane. The Ca2q ions
bound to this convex side serve a bridging function
and coordinate not only to the protein but also to
phosphoryl moieties of the membrane phospholipids.
Moreover, it appears that in the four repeat annexins
the conformation of the molecule is not grossly al-
w xtered upon membrane binding 39,42–49 . The latter
is however different in annexin VI which comprises
eight annexin repeats folded into two similar halves
each representing a typical annexin core. Upon mem-
brane binding these two halves are rotated about 908
relative to one another to assume a coplanar arrange-
w xment with the membrane 34,35 . The principles gov-
erning Ca2q binding and Ca2q-mediated phospho-
lipid binding established for the crystalized annexins
most likely also apply to the proteins in solution.
Using site-directed mutagenesis approaches the cap
residues of individual type II Ca2q sites as well as
residues in or close to the loop between helices a and
b were shown to be crucial for high-affinity Ca2q–
w xlipid binding 50–54 . Although the general folding
of the protein core domain is highly similar for the
different annexin analyzed so far the number and
exact location of the individual Ca2q sites appears to
w xdiffer between members of the family 30–35,41 .
This could be the basis of the different Ca2q sensitiv-
ities and phospholipid specificities observed for dif-
ferent annexins.
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While the common structural principles and bio-
chemical properties of annexins reside in the well-
conserved protein core domain, specificity with re-
spect to the function of individual annexins is thought
to be conferred through the N-terminal domain pre-
ceding the protein core. This domain, also called
head or tail, is sensitive to limited proteolysis and
differs in length between 11 to 19 annexins III, IV,
.V, VI, X, XII, XIII and more than 100 residues
 .  w xannexins VII and XI for review see 5 ; a schematic
.overview is given in Fig. 1 . The sequences of the
N-terminal domains are highly variable and with the
exception of the short-tail annexins III, V and XII
w x28,31,32 their three dimensional folding and loca-
tion with respect to the protein core is not known.
N-terminal domains of the short-tail annexins appear
to be restricted to the concave side of the proteins
and are possibly involved in the regulation of ion
conductance through the central hydrophilic pore
w x32,36 . More complex modes of regulation can be
discussed for the longer N-terminal domains of the
larger annexins. Through direct intramolecular inter-
actions they could affect the Ca2q and phospholipid
binding sites located on the convex side of the core
domain. Likewise, properties of the core domain
could be altered through conformational changes in-
duced by the N-terminal tail domain. Such modulat-
ing activity of the N-terminal domain has been
demonstrated in vitro and in vivo for several longer-
tail annexins, in particular annexins I and II. In
phospholipid binding experiments, for example, re-
moval of the N-terminal domain in annexins I and II
leads to an increased affinity towards Ca2qrphos-
w x 2qpholipid 55–57 . An increase in the Ca affinity of
annexin I is also observed in the presence of antibod-
w xies directed against the tail domain 58 whereas such
antibodies and certain cleavages in the N-terminal
domain have an inhibitory effect on the vesicle ag-
w xgregation property displayed by this annexin 15,59 .
More directly, a modulating effect of the N-terminal
domain of annexin I has been confirmed by analyzing
the lipid vesicle binding and aggregation properties
of chimeric annexin proteins consisting of an N-
terminal portion of annexin I and C-terminal parts of
w xannexin V 12,60,61 . In vivo, the importance of an
N-terminal annexin domain has been documented
through the ectopic expression in baby hamster kid-
 .ney BHK cells of N-terminally truncated versions
of annexin I. Here, residues 13–26 of the N-terminal
domain have been shown to be involved in specifying
w xthe early endosomal localization of the protein 62 .
The regulatory importance of the N-terminal do-
main is also underscored by the fact that it often
harbours phosphorylation sites for signal transducing
 w x.protein kinases for reviews see 3,5 . In the case of
annexins I and II consequences of such regulatory
phosphorylations have been documented in phospho-
lipid vesicle binding and aggregation experiments.
Phosphorylation by the EGF receptor kinase at Tyr-20
of annexin I, for example, renders the protein more
susceptible to proteolytic degradation thus altering in
turn its Ca2qrphospholipid binding and vesicle ag-
 w x.gregation properties for review see 5,63 . In muta-
genesis experiments, a substitution of Tyr-20 by a
negatively charged amino acid mimicking to some
extent the phosphorylation by the EGF receptor ki-
nase results in an enhanced Ca2q requirement of the
w xmutant protein for promoting vesicle aggregation 59 .
Similar effects are observed when Ser-26, a site for
phosphorylation by protein kinase C, is replaced by
w xaspartate or glutamate 16,59 . Annexin II also con-
tains a tyrosine residue in its N-terminal domain
which functions as a phosphorylation site in this case
src  w x.for pp60 for review see 64,65 . Phosphorylation
at this Tyr-23 decreases the affinity of annexin II for
phospholipids in liposome binding experiments and
abolishes the chromaffin granule aggregation activity
displayed by this annexin at micromolar Ca2q levels
when complexed with its cellular protein ligand p11
w x55,66 . Protein kinase C phosphorylation of annexin
II occurring in the N-terminal domain, on the other
hand, has no effect on the Ca2q-dependent lipid
binding of the protein but significantly decreases the
rate and extent of the annexin II-mediated lipid vesi-
w xcle aggregation 67 . This finding, however, appears
to contradict the observation that protein kinase C-
mediated phosphorylation of Ser-25 of annexin II is a
prerequisite for an activity of the annexin II–p11
complex in the Ca2q-evoked secretion in permeabi-
w x  .lized chromaffin cells 68 see below . While all in
vitro data strongly favour the notion that the N-termi-
nal domain of an annexin modulates properties dis-
played by the conserved core domain and that this
modulation can be regulated by phosphorylation, di-
rect in vivo observations supporting this view are still
lacking. Subcellular fractionation and immunoisola-
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tion of certain endocytotic structures, the multivesicu-
 .lar bodies MVBs , indicate that within 3T3 cells
overexpressing the human EGF receptor annexin I is
associated with MVBs in a Ca2q-independent manner
and that phosphorylation of annexin I by the EGF
receptor kinase occurring in the MVBs converts it
into a form requiring Ca2q for the membrane associa-
w xtion 69 . However, this might not be a general
phenomenon since the membrane association of an-
nexin I in BHK cells appears to be strictly Ca2q-de-
w xpendent 62 .
The N-terminal domains of annexins also harbour
other sites for posttranslational modifications likely
to be of regulatory importance. These include a glu-
tamine residue at position 18 of the annexin I tail
which is the site for a transglutaminase cross-link to
another annexin I chain. The resulting annexin I
homodimer has an increased Ca2q sensitivity for
phospholipid binding and associates with A431 cell
membranes in an EGTA-resistant, i.e. Ca2q-indepen-
w xdent manner 70,71 . In the case of annexin XIIIa,
Ca2q-insensitive membrane association is achieved
through N-terminal myristoylation, a property most
likely shared by different N-terminal splice variants
w xof this protein 72,73 . Whether other annexins are
also modified by myristoylation or some other type
of fatty acid attachment remains to be determined.
2.3. Annexin protein ligands
Several protein ligands which appear to be unique
for individual annexins and affect properties dis-
played by the proteins in vitro have been identified.
As can be expected from the modular structure of the
annexins most ligand binding sites have been mapped
to the unique N-terminal domain of the respective
annexin. Interestingly, several members of the S-100
family of EF-hand type Ca2q-binding proteins form
complexes with different annexins. The prototype of
such complexes identified more than 10 years ago is
the annexin II–p11 heterotetramer in which a dimer
 .of the S100 protein p11 S100A10 links two annexin
w xII molecules 74–76 . p11-induced complex forma-
tion is of regulatory importance as it markedly re-
duces the Ca2q requirement for phospholipid binding
and chromaffin granule aggregation by annexin II
w x55,77 . Moreover, the annexin II–p11 complex has
an altered subcellular localization as compared to
monomeric annexin II and complex formation ap-
pears to be a prerequisite for tightly anchoring this
annexin in the cortical cytoskeleton of fibroblasts and
w xadrenal chromaffin cells 78–80 . Hydrophobic forces
predominantly contribute to the stabilization of the
annexin II–p11 interaction and the hydrophobic
amino acid side-chains involved have been mapped
to the N-terminal domain of the annexin and the
unique C-terminal extension of the S100 protein
w x81,82 . In the case of annexin II, the entire p11
binding site is contained within the N-terminal 14
amino acid residues and synthetic peptides of this
sequence compete effectively with full-length an-
w xnexin II for p11 binding 81,83 . These structural
informations have led to the introduction of synthetic
peptides and fusion proteins containing the N-termi-
nal annexin II sequence in functional studies see
.below .
The other two annexin–S100 pairs identified more
recently are the annexin I–S100C and the annexin
 . w xXI–calcyclin S100A6 complexes 84–87 . In both
cases, the S100 binding site has again been mapped
to the N-terminal domain of the respective annexin
w x86–88 . However, it is not known whether binding
of the dimeric S100 protein leads to the formation of
a heterotetrameric unit and what the physiological
consequences of the complex formations are. Regula-
tion by Ca2q binding to the S100 protein marks a
difference in the case of the annexin I–S100C and
annexin XI–calcyclin complexes when compared to
the annexin II–p11 heterotetramer. While the former
complex formations are strictly Ca2q-dependent the
latter occurs in the absence of Ca2q. This is due to
the deletion and substitution of Ca2q-coordinating
residues in the EF-hand loops of the p11 molecule
which render the protein inactive in Ca2q binding
and most likely freeze it in a conformation competent
w xfor binding to its ligand annexin II 89 . Using an
affinity chromatography approach another Ca2q bind-
ing protein of the EF-hand superfamily has recently
been identified as an annexin ligand. Sorcin, a 22-kDa
protein containing four EF-hand motifs in contrast to
.the two EF-hand sites in S100 proteins which is
homologous to the calpain light chain, binds to the
w xlong N-terminal domain of annexin VII 90 . This
N-terminal domain in annexin VII is similar to the
 .one found in annexin XI Fig. 1 and composed of
 .repetitive sequence stretches rich in glycine G , tyro-
( )V. Gerke, S.E. MossrBiochimica et Biophysica Acta 1357 1997 129–154 135
 .  .sine Y and proline P residues which have been
w xproposed to form a pro-beta helix 91 .
Other proteins shown mainly by biochemical ap-
proaches to bind to members of the annexin family
include a number of cytoskeletal or cytoskeleton-
associated proteins. Annexins I, II and VI, for exam-
ple, bind in a Ca2q-regulated manner to filamentous
w xactin 20,74,92,93 . This interaction has been studied
most extensively in the case of annexin II where a 9
amino acid sequence in the third annexin repeat was
w xreported to represent the actin binding site 94 . An-
nexin II in its heterotetrameric complex with the p11
dimer is also capable of bundling actin filaments at
micromolar Ca2q concentrations and this bundling as
well as the F-actin binding is inhibited by pp60src-
catalyzed tyrosine phosphorylation of annexin II
w x66,74 . The physiological significance of the
bundling activity is, however, questionable since an-
nexin II appears to be excluded from stress fibers in
w xfibroblasts 95 . In contrast the binding of annexin II
to F-actin is consistent with the localization of both
proteins to the cortical cytoskeleton of a variety of
 w x.cells for review see 64 . Members of the non-
erythroid spectrin family are also found in this sub-
membraneous structure and represent in vitro ligands
w xfor annexin II and annexin VI 74,96,97 , indicating
that at least some annexins might serve a structural
 .function in this cortical region of the cell see below .
While cytoskeletal binding partners for annexins, in
particular annexin II, generally appear to be compo-
nents of the microfilament system, exceptions from
this rule exist, e.g. the Ca2q-dependent binding of
annexin II to the intermediate filament protein GFAP
 . w xglial fibrillary acid protein observed in vitro 98 .
The above does not represent a complete list of all
intracellular binding proteins identified to date this
.would go beyond the scope of this review but it
illustrates two features widespread among the annex-
ins. First, proteins of this family often represent
targets for regulation through S100 protein binding.
Second, annexins or annexin–S100 complexes can
associate not only with membranes but also with
cytoskeletal proteins, in particular with those found in
cytoskeletal structures underlying membranes.
In addition to the examples discussed above, pro-
teins or structures found on the external surface of
cells have also been identified as annexin ligands.
These include proteins of the extracellular matrix
w xsuch as collagen, which binds annexin V 99 , and
tenascin C, which was reported to interact with an-
nexin II exposed on the surface of endothelial cells
w x100 and whose mitogenic stimulation of endothelial
cells is blocked by antibodies against annexin II
w x101 . Endothelial annexin II also was shown to act as
 .a receptor for tissue plasminogen activator t-PA and
to enhance the t-PA dependent plasminogen activa-
w xtion 102,103 . Another plasma protein interacting
with annexins is apolipoprotein A1 which binds to
annexins I and VII, but not annexins IV and VI, in a
2q w xCa -dependent manner 104 . In some cases, annex-
ins have been implicated in intercellular interactions.
These include annexins II and VI, which were identi-
fied as lymphoma cell membrane components partici-
pating in the divalent cation-dependent endothelial
w xcell adhesion 105,106 , and annexin I, which was
w xshown to bind to leukocytes 107 and was proposed
to act anti-inflammatory by interfering with the
w xtrans-endothelial migration of leukocytes 108 . Cell
surface receptors for these annexins have not been
identified but it is interesting to note in this respect
w xthat annexin VI binds to carbohydrate structures 109
and that annexins I and II appear to be choline
w xbinding proteins 110 .
Annexin binding to the extracellular structures
listed above as well as the anti-coagulant and anti-in-
flammatory activities reported for several annexins
 w x.for review see 5 critically depend on the extracel-
lular presentation andror secretion of annexins. The
experimental data for a specific secretion of certain
annexins are still rather scarce with the most convinc-
ing evidence coming from the quantification of an-
nexin concentrations in the seminal plasma from the
human prostate gland. While annexins I, IV and V
are expressed at comparable levels in the ductal
epithelium of the gland, only annexins I and V, but
not annexin IV, are found at considerable levels in
w xthe extracellular fluid 111 . However, we are still in
need for more clear cut evidence for the active
release of annexins from cells, e.g. through pulse-
chase labelling of cultured cells and a careful analysis
of the released proteins. Moreover, there is so far no
satisfactory model providing a mechanistic basis for a
specific release of the proteins annexin cDNAs, for
example, do not contain sequences encoding hy-
.drophobic signal peptides . Conceptually, annexins
could be released after membrane breakdown, a sce-
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nario possibly met in the case of matrix vesicles
present in the extracellular matrix of mineralizing
tissues. Matrix vesicles which are derived from chon-
drocyte microvilli contain several annexins and are
also enriched in sphingomyelin, cholesterol and phos-
phatidylserine, i.e. lipids annexins are known to inter-
act with directly or when present in certain mem-
w x  .brane domains 112,113 see also below . Upon
break down of the matrix vesicles occurring during
bone formation, annexins present in the vesicles could
be released into the extracellular milieu.
3. Annexin ion channels
Arguments have continued about the functions of
annexins since it was first proposed that annexin I is
a mediator of the anti-inflammatory response. Claim
is followed by counter-claim and the functional ques-
tions remain largely unanswered. One of the most
recent and provocative suggestions is that members
of the annexin family are ion channels. Here, we
review the evidence both for and against this role and
consider the physiological context in which such ion
channels might operate. The first report of ion chan-
nel activity for any annexin was by Rojas and Pollard
w x  .114 who showed that purified annexin VII synexin
formed capacitative gating currents in acidic phos-
pholipid bilayers. The same group then demonstrated
that annexin VII formed highly selective, voltage-
2q w xsensitive Ca channels in artificial membranes 115 .
This work was extended to show that purified and
w xrecombinant annexin V had similar activity 116 .
At the same time, Huber et al. published the
w xcrystal structure of annexin V 28 . This crystal struc-
 .ture see above revealed features consistent with
annexin V being an ion channel. First, the centre of
the molecule forms a pore which was suggested to be
the ion conductance pathway. Second, the fact that
the pore is lined by the side-chains of acidic amino
acids explains why the annexin V channel exhibits
selectivity for cations. Finally, the pore was oriented
perpendicular to the convex surface of the annexin V
molecule on which the Ca2q-binding sites are located
and which is the surface that interacts with phospho-
lipids. Huber et al. proposed a model in which the
convex surface of annexin V lies in close apposition
to the inner leaflet of the plasma membrane — this is
consistent with the known phospholipid-binding pref-
erences of annexin V — with the hydrophilic channel
providing a cation-selective gateway to the cell inte-
w x  .rior 39 see Fig. 2 for a model .
3.1. E˝idence for and against the annexin ion chan-
nels
Despite the electrophysiological data and the sup-
porting structural studies, which clearly show that
annexin V has ion channel activity, several important
questions have yet to be answered if the ion channel
theory is to gain acceptance. First, the idea of an ion
channel that does not span the plasma membrane
presents obvious conceptual problems. Karshikov et
w xal. 117 countered this by proposing a mechanism
based on hypothetical calculations, in which annexin
V could electroporate the membrane causing a lo-
calised area of increased permeability through which
extracellular ions would flow. The selectivity of the
channel for calcium would ensure the exclusion of
other ions. A more direct answer to the question of
membrane spanning came with the description of a
w xhexameric form of annexin XII 31 . Here, the six
annexin XII monomers are arranged as a sandwich of
two trimers. An unexpected feature of this structure
was that the convex faces of the six annexin units
were all buried at the intermolecular face of the two
trimers. In addition to providing a functional unit
with the necessary molecular dimensions to span the
plasma membrane, the hexamer also had a central
pore lined with the side-chains of charged amino
 .acids Fig. 2 . In the case of annexin XII these
residues are basic, suggesting an anion rather than a
cation channel.
A hexameric annexin is also structurally more
acceptable than a monomeric annexin because of the
larger size of the central pore. In the hexamer the
˚most constricted part of the pore is 8 A in diameter as
˚opposed to 1 A for monomeric annexin V. The larger
pore is more consistent with the known conductance
values for annexin V. Interestingly, a theoretical hex-
americ model of annexin V forms a structure with a
central pore lined with acidic residues, but different
ones from those that line the pore in monomeric
annexin V. As yet, no annexin V hexamer has been
described although annexin V trimers are well docu-
w x 2qmented 47 . If annexin V does function as a Ca -
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channel is it as a hexamer which is structurally
acceptable but may not exist, or a monomer, which
exists but which less readily conforms to the general
perception of an ion channel. In favour of the latter
model, Huber et al. showed that point mutation of a
glutamic acid residue in the central pore of monomeric
annexin V changes the ion selectivity from Ca2q to
q w xNa 10 . Other mutational studies demonstrated the
importance of specific amino acids in voltage sensing
and ion permeability, which together lend weight to
the idea that monomeric annexin V can form a
functional Ca2q-channel.
Another concern is that as more annexins have
their structures solved the list now includes annexins
.I, II, III, V, VI and XII it is becoming clear that
almost all display ion channel activity in vitro. This is
not unlike the position ten years ago, when after the
excitement of discovering that annexin I was an
inhibitor of phospholipase A , it gradually became2
clear that there were at least nine other annexins with
identical activity. This does not rule out the possibil-
ity that annexin I is an inhibitor of phospholipase A 2
or that annexin V is an ion channel, but it does raise
questions about why members of such an expansive
gene family should all be doing the same thing. In
fact, the anti-inflammatory role for annexins is not a
strictly accurate historical precedent because there are
important differences between annexins with respect
to their ion channel properties. Annexin III has little
channel activity and as mentioned earlier, annexin
XII lacks detectable cation channel activity and is
more likely to form an anion channel. An interesting
observation emerging from structure-function studies
on the annexin ion channels is that channel activity
appears to depend not only on the central pore, but
also on the N-terminal domains. Removal of these
domains in annexins II and V virtually abolishes
w xchannel activity 33,118 and replacement of a trypto-
phan residue with an alanine in the N-terminus of
annexin III enhances calcium channel activity B.
Favier-Perron, F. Russo-Marie, A. Lewit-Bentley and
.R. Huber, pers. commun. . These are further exam-
ples of how annexin N-termini are likely to be impor-
tant regulatory domains.
3.2. Is there a physiological annexin ion channel?
A third criticism is that in in vitro systems
molecules that are clearly not physiological ion chan-
nels can integrate into a phospholipid bilayer and
Fig. 2. Ion conductance by annexins. The figure shows two models for annexin ion channels. On the left, a monomeric annexin binds
Ca2q-dependently to the inner leaflet of the plasma membrane. It is proposed that the convex surface of the annexin generates a localised
region in which the phospholipid bilayer is disturbed and that under conditions of membrane depolarization or hyperpolarization, the
w xmembrane becomes leaky 117 . The central pore of the annexin acts as an ion filter, in the case of annexin V the filter is selectively
permeable to Ca2q. On the right, an annexin homohexamer forms a membrane-spanning structure in which two trimers are joined
Ca2q-dependently at their convex faces. A pore is formed at the centre of the hexamer, which is suggested to be the ion conductance
w xpathway 31 .
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generate ion channel activity. Thus, a 21 amino acid
synthetic peptide consisting of only serine and leucine
will form a cation-permeable pore in a lipid bilayer
w x119 . The channel activity of annexins may also be
 .artefactual, although the observations that: 1 despite
their overall similarity not all annexins form chan-
 .nels; and 2 mutation of specific residues in the
central pore of annexin V switches the ion selectivity
from Ca2q to Naq, tend to argue against this. Never-
theless, the challenge now is to demonstrate that
annexins form functional ion channels in living cells.
Virtually all cells use Ca2q as a second messenger
and tight regulation of free intracellular Ca2q concen-
w 2qxtration Ca is critical for normal cell function.i
The transient opening of Ca2q channels to either
intracellular stores andror the extracellular milieu
w 2qxleads to increases in Ca , which contribute to ai
variety of cellular responses including contraction,
exocytosis and growth depending on the cell type and
the initiating stimulus. Several of the key players in
this process have now been identified, for example,
the ligand-gated ryanodine receptors and IP recep-3
tors that regulate release of Ca2q from intracellular
w xstores 120 , and the voltage-gated L-, N- and T-type
channels that conduct Ca2q across the plasma mem-
brane in excitable cells such as neurones and muscle
fibres.
Calcium channels in non-excitable cells appear in
various guises, as calcium-release activated channels
 .  .CRACs , store-operated calcium channels SOCs
 . w xand receptor-operated calcium channels ROCs 121 .
These are the channels that mediate calcium entry in
T lymphocytes, hepatocytes, smooth muscle cells,
platelets, neutrophils, endothelial cells and fibrob-
lasts. Ca2q entry in these non-excitable cells is poorly
understood and for reasons outlined below, it is here
that annexins can be included with certain other
molecules as candidate Ca2q channels. The best char-
acterised of the potential CRACs, ROCs and SOCs
 .are the transient receptor potential trp and trp-like
genes in Drosophila for which mammalian homo-
w xlogues have recently been discovered 122 , and which
enhance Ca2q entry when transiently expressed in
COS cells or block Ca2q entry when expressed in
antisense orientation. The two features of trp that
make it a good candidate for a Ca2q entry channel
are that it is gated by depletion of the intracellular
Ca2q stores and is inhibited by La3q but is insensi-
tive to the dihydropyridine blockers such as nifedip-
ine that block the classic voltage-gated Ca2q chan-
nels.
Annexins are candidates for similar reasons. First,
they tend to be much more abundant in non-excitable
cells such as lymphocytes, epithelial cells and hepato-
cytes than in neurones. Second, Ca2q entry in non-
excitable cells is usually driven by membrane hyper-
polarisation and the annexin V channel conducts
Ca2q in response to both depolarising and hyperpo-
w x 2qlarising potentials 117 . Third, Ca channels in
non-excitable cells are inhibited by La3q but are
insensitive to dihydropyridine blockers, again this is
identical to the known pharmacology of the annexin
V channel. Finally, annexin V has a Ca2q conduc-
tance similar to those of electrophysiologically char-
w xacterised channels in non-excitable cells 121 . These
may be coincidences but because the Ca2q channels
in question have yet to be identified at the molecular
level, annexin V and trps both remain reasonable
candidates.
3.3. Annexins as ion channel regulators
To add further confusion to an already complicated
picture, it appears that in addition to having their own
intrinsic channel activity, annexins may also modu-
late the activity of other ion channels. This was first
w xdemonstrated by Diaz-Munoz et al. 123 who showed
that purified annexin VI increased the mean open
time and opening probability of sarcoplasmic reticu-
lum Ca2q channels in an isolated membrane prepara-
tion. Although this effect was shown to be specific to
annexin VI, it required the presence of the protein on
the lumenal side of the membrane, and annexin VI
like other annexins is generally thought to be a
cytosolic protein. Recently, Huber et al. solved the
crystal structure of annexin VI and demonstrated that
the purified protein, like annexins II and V, has Ca2q
w xchannel activity 34 . This raises the possibility that
the apparent increase in channel activity observed by
 .Diaz-Munoz et al. above was in fact due to annexin
VI itself and not the consequence of an interaction
between annexin VI and the sarcoplasmic reticulum
Ca2q channels.
To address the question of whether or not annexin
VI is involved in regulation of Ca2q homeostasis in
vivo, Dedman’s group recently generated the first
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annexin transgenic mice, in which annexin VI was
over-expressed in the heart under the control of the
w xmyosin heavy chain gene promoter 124 . These mice
exhibited various cardiac problems and those with
highest levels of expression died of heart failure
shortly after birth. However, using Ca2q-sensitive
fluorescent dyes and isolated cardiac myocytes from
these transgenic mice, it was shown that cells with
increased levels of annexin VI had a lower resting
Ca2q level and generated smaller Ca2q spikes on
electrical stimulation. The mechanism of annexin VI
action in cardiac myocytes is not understood but if
the function of annexin VI is to suppress Ca2q
mobilisation then this implies that annexin VI might
inhibit exocytosis in secretory cells or reduce the
growth rate of proliferating cells. In this context it is
interesting that purified annexin VI inhibits annexin
w xII-mediated chromaffin granule aggregation 125,126
and that heterologous expression of annexin VI in
A431 carcinoma cells reduces their growth rate
w x127,128 .
Annexin IV is expressed in columnar epithelial
cells of various tissues including intestine, lung,
stomach, trachea, kidney, fallopian tube and uterus.
Together with the preferential localisation of annexin
IV to the apical membranes of polarised secretory
epithelial cells in the intestine this suggests a possible
role in fluid secretion. As chloride ions are the major
secreted anion, and the apical membrane is the pri-
mary site for regulation of chloride secretion, Kaetzel
w xet al. 129 examined whether or not annexin IV
might be a modulator of chloride channel activity.
They showed that introduction of purified exogenous
annexin IV into a colonic cell line through a patch
pipette specifically blocked Ca2q-dependent Cly cur-
rent activation. This effect was reversed both by an
affinity-purified antibody to annexin IV and by an
antisense oligonucleotide complementary to the an-
nexin IV mRNA. The same group then showed that
annexin IV may exert its inhibitory role on Ca2q-de-
pendent Cly current activation by blocking phospho-
rylation of the Cly channel by calmodulin-dependent
 . w xprotein kinase II CaMKII 130 .
It will be some time before we have a clear picture
of how, or indeed if, annexins function either as ion
channels or ion channel regulators in vivo. However,
it must be hoped that further identification of annex-
ins in cellular pathways involved in the regulation of
ion channel activity, will provide new therapeutic
targets for diseases such as cystic fibrosis in which
normal ion channel function is compromised.
4. Gene expression
Annexins are often described as ‘‘ubiquitous’’,
and as a family this is true, but individual annexins
have discrete patterns of expression, presumably re-
flecting singular mechanisms of gene regulation re-
lated to cell-type specific functions. Some family
members are widely expressed, for example annexins
I, II and VI, whereas others such as annexins VIII
and XIII are expressed in very few cell types. Any
one cell type might express up to ten different annex-
ins, so it is possible that each cell type has its own
unique annexin ‘‘fingerprint’’. In this section we
review the current perception of annexin gene regula-
tion and discuss how this correlates with ideas about
annexin function.
4.1. Annexin gene regulation
Several annexin genes have been cloned and the
close structural relationship of the annexin proteins is
mirrored by strikingly conserved patterns of genomic
organisation. The positions of intron–exon bound-
aries within the regions of annexin genes correspond-
ing to the protein repeats, are at identical locations
for all mammalian annexins. The relationship be-
tween genomic organisation and protein structure has
w xbeen reviewed elsewhere 131 . In contrast, there is
no similarity in the genomic organisation of the first
coding exons that specify the divergent annexin N-
terminal domains. However, examination of the ge-
nomic structures of annexins can provide clues as to
functional domains. This is exemplified by the an-
nexin II gene in which the first exon encodes the
w xp11-binding domain 132 and the second exon en-
codes a domain recently demonstrated to mediate
w xbinding to endosomes 133 .
Relatively little is known about annexin gene regu-
lation in terms of defining active regions within
promoters. Genomic sequences upstream of the tran-
 .scription start sites TSS have been described for
w xhuman annexins I, II, V and VI 134–137 and most
of these contain recognisable elements in keeping
with these domains being functional gene promoters.
( )V. Gerke, S.E. MossrBiochimica et Biophysica Acta 1357 1997 129–154140
Consistent with annexins having distinct expression
patterns, the putative promoters have little if any
sequence similarity. Annexins I, II, V and VI all have
CAAT and TATA boxes within these upstream se-
quences although in the annexin VI promoter they lie
somewhat distal to the TSS and in deletion experi-
ments appear to be functionally redundant S.R. Don-
.nelly and S.E. Moss, unpublished observations . In
contrast, in the annexin I gene promoter, analysis of
the activity of a series of 5 deletions revealed that the
region containing the CAAT and TATA boxes pos-
sesses full promoter activity S.R. Donnelly and S.E.
.Moss, unpublished observations . Imai and Kohsaka
w x138 recently described two promoters for the rat
annexin V gene, one of which is very GC-rich and
lies proximal to the TSS and a second promoter
several kilobases upstream which contains putative
binding sites for early response genes such as AP1.
This is consistent with the findings of Braselmann et
w xal. 139 who discovered annexins V and II as fos-in-
ducible genes.
It is not known why annexin V has two separate
promoters, but sequencing of alternatively spliced
transcripts showed that both are functional and that
transcription from the distal promoter splices out the
exon lying immediately downstream of the proximal
w xpromoter. Imai and Kohsaka 138 also showed that
alternative splicing of transcripts originating from the
distal promoter could generate an mRNA in which
the usual first coding exon was absent and from
which an annexin V variant lacking the N-terminal
25 amino acids would be produced. An intriguing
possibility is that following cell activation and c-fos
induction, cells start to synthesise the N-terminally
truncated annexin isoform. If annexins function as
multimers then this truncated form could act as a
dominant interfering mutant, blocking the activity of
the existing cellular pool of annexin V. In support of
w xsuch a model, Berendes et al. 118 have already
shown that an annexin V mutant lacking the N-termi-
nal domain does not have Ca2q-channel activity.
The most detailed study of an annexin promoter to
w xdate is for the pigeon Annexin I gene 140 .cp35
Horseman and co-workers initially discovered An-
nexin I when searching for genes induced bycp35
prolactin in the pigeon cropsac. In pigeons there are
at least two annexin I genes, one of which closely
resembles mammalian annexin I, is constitutively
expressed and like its mammalian counterpart is in-
sensitive to prolactin, and Annexin I which is alsocp35
very similar to mammalian annexin I but lacks the
tyrosine phosphorylation site for the epidermal growth
factor receptor and which is absolutely reliant on
w xprolactin for expression 141 . A region of the An-
nexin I promoter close to the TATA has beencp35
identified which binds to putative transcription fac-
tors only in prolactin-stimulated cropsac. Molecular
cloning of these factors will provide new insight into
both annexin gene regulation and the mechanism of
prolactin-induced gene expression. The question as to
why pigeon cropsac should have two annexin I genes
remains unanswered, but again there is the possibility
that the inducible form lacking the tyrosine phospho-
 .rylation site Annexin I somehow interferes withcp35
the activity of the constitutively expressed form.
4.2. Cell growthrdifferentiation
The discovery that some annexins are fos-induci-
ble raises the possibility that they have roles in cell
growth andror differentiation. There are several in-
stances where cell differentiation is accompanied by
an increase in annexin expression, for example, an-
nexin I is up-regulated during differentiation of HL60
w xand U937 myelomonocytic cells 142,143 , annexin II
is up-regulated during nerve growth factor-induced
differentiation of PC12 phaeochromocytoma cells
w x144,145 and annexin VI is up-regulated during B-
w xand T-lymphocyte development 146 . As a general
rule, annexins tend to be more highly expressed in
terminally differentiated cells, examples of annexin
down-regulation are rare and normally linked to ac-
quisition of a specialist phenotype, for example,
down-regulation of annexin VI in the ductal epithelial
 .cells of lactating as opposed to non-lactating breast
w xtissue 146 .
Annexin expression is also variable and dependent
w xon cell growth state. Schlaepfer and Haigler 144
showed that the levels of annexins I and V change in
fibroblasts according to factors such as cell density
and renewal of growth medium. The question is
whether or not changes in annexin expression that
occur during cell differentiation or proliferation are a
consequence of these processes, or do annexins actu-
ally contribute some important activity or driving
force. At present, there is little evidence to support or
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repudiate either argument. Most studies of annexins
in development have been descriptive and whilst
these may suggest certain roles, proof has not yet
w xbeen forthcoming. Carter et al. 147 showed that
annexin II is up-regulated during embryonic avian
limb development, being virtually undetectable at day
5 of development but strongly expressed by day 14.
If cells were dissociated at day 5 and grown in
culture then annexin II expression was rapidly in-
duced, but only if the cells were allowed to attach to
a substratum. This reinforces the view that cell cul-
ture conditions are an important determinant of an-
nexin expression. Similar developmental changes in
annexin expression have been reported in the fish
w xembryo 148 , the embryonic rodent nervous system
w x149–151 and diverse other tissues.
In cultured cells the causal relationship problem is
the same, but perhaps a little less intractable since
annexin expression can, at least to some extent, be
w xmanipulated. Masiakowski and Shooter 152 showed
that transfection of p11, the cellular ligand of annexin
II, into PC12 cells stimulated differentiation into cells
resembling sympathetic neurones. Whether this was
accompanied by increased expression of annexin II
 .as seen with NGF-induced PC12 differentiation is
w xnot known. Puisieux et al. 153 reported that in cells
expressing p11 mRNA, p11 protein was undetectable
unless annexin II was also expressed, suggesting that
p11 probably cannot function alone and that annexin
II contributes to PC12 cell differentiation. In contrast,
F9 mouse teratocarcinoma cells show an expression
of p11 both at the mRNA and at the protein level
w xwhereas annexin II appears to be absent 154,155 .
In other cell types annexins may function to mod-
erate or inhibit cell proliferation. This was first shown
for A549 lung adenocarcinoma cells which dramati-
cally reduce their growth rate when cultured in the
w xpresence of recombinant annexin I 156 . Growth
arrest was also observed when A549 cells were cul-
tured in the presence of dexamethasone, which coin-
cidentally stimulates the appearance of annexin I on
w xthe cell surface. Subsequently, Croxtall et al. 157
showed that inhibition of A549 cell proliferation
could be mimicked by N-terminal peptide fragments
of annexin I. The active fragments incorporated amino
acids 13–25 and 21–33 whereas a peptide corre-
sponding to amino acids 1–12 the S100C-binding
.domain was inactive. The squamous epithelial carci-
noma cell line, A431, was also shown to be growth-
w xinhibited by annexin VI 127 . These cells do not
normally express annexin VI but when stably trans-
fected clones expressing annexin VI were examined
in proliferation assays, they were found to grow more
slowly in a serum concentration-dependent manner.
 .Thus, at low serum concentrations 1–2% , wild-type
A431 cells grow normally whereas A431 cells ex-
pressing annexin VI become growth-arrested and ac-
cumulate in the G phase of the cell cycle. Theobald1
w xet al. 128 then showed that despite appearing to
have partially reverted to a non-transformed pheno-
type, annexin VIq A431 cells were still tumorigenic
in immunodeficient mice, although the tumours grew
signficantly more slowly than those derived from
control transfected cells. These data argue that annex-
ins are not just ‘‘innocent bystanders’’ in important
cellular processes such as growth regulation and dif-
ferentiation and that they probably have pro-active
roles which remain to be elucidated.
5. Involvement in membrane traffic and mem-
brane organization
The common property displayed by annexins in
vitro, i.e. the Ca2q-dependent binding to acidic phos-
pholipids found preferentially in the cytosolic leaflet
of cellular membranes, is highly suggestive of a
function of the proteins in intracellular membrane-re-
lated events. To some extent this has been a dogma in
the field since already the first annexin described in
the literature, annexin VII at the time known as
.synexin , was isolated as a protein mediating mem-
w xbrane contact and fusion 158 . While these are in-
deed properties shared by several annexins detailed
analyses in the years following the initial discovery
of annexin VII revealed that in most cases the Ca2q
concentration required to achieve vesicle aggregation
 . 2qand fusion are above the cytosolic free Ca levels
experienced in resting and even stimulated cells see
.above . This still remains to be a main conceptual
problem in the annexin field. However, at least an-
nexins I and II appear to be able to associate with
membranes in vitro at micromolar or even submicro-
molar Ca2q levels and several members of the family
have been localized in situ to intracellular membranes
andror the plasma membrane at the light and elec-
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tron microscope level. Moreover, recent studies have
provided evidence for Ca2q-independent annexin–
membrane interactions and an involvement of annex-
ins in specific membrane trafficking events. Here we
discuss these aspects of annexin biology in light of
the intracellular distribution of individual members of
the family.
5.1. Intracellular localization and potential target
membranes for indi˝idual annexins
A clear view with respect to the intracellular distri-
bution and the specific allocation of individual annex-
ins to one or more membranous structures is ob-
scured by the different cell types, fixation methods
and antibodies used in a substantial and ever increas-
ing number of immunocytochemical studies on an-
nexins. Below we summarize some of these data for
the major mammalian annexins trying to obtain a
conclusive picture for the individual proteins. We do
not intend to present a complete literature survey and
we do not include data which contradict the general
picture obtained for a given annexin and appear only
once in the literature.
Taking this into account membrane-bound annexin
I appears to reside on the plasma membrane and on
the membranes of certain endocytotic and phagocytic
structures. The latter is particularly evident in
macrophages, where annexin I was localized to early
endosomal and phagosomal membranes at the ultra-
structural level Diakonova, M., V. Gerke, J. Ernst,
G. van der Vusse, G. Griffiths, submitted for publica-
.tion , and in neutrophils, where annexin I was shown
to translocate from the cytosol to the phagosomal and
the plasma membrane when the cells are stimulated
with opsonized zymosan or take up opsonized yeast
w x  .159,160 . In baby hamster kidney BHK and
 .Madin-Darby canine kidney MDCK cells annexin I
is present on the plasma membrane and on the mem-
w xbrane of early endosomes 62 , whereas in NIH 3T3
cells overexpressing the EGF receptor annexin I is
w xfound on multivesicular endosomes 69 . Under cer-
tain conditions or in some cell types annexin I may
also associate with other structures as it is present on
insulin-containing granules in pancreatic beta-cells
and appears to interact to some extent with cyto-
w xskeletal structures in human keratinocytes 161,162 .
A similar but not overlapping subcellular distribu-
tion is often found for annexin II although these two
 .annexins I and II are only co-expressed in a limited
number of cell types for a recent comparison of the
tissue distributions of annexins I and II, see Dreier,
R., K.W. Schmid, V. Gerke, K. Riehemann, submit-
.ted for publication . Annexin II is a general con-
stituent of the submembraneous cytoskeleton for
w x.review see 64 and has also been identified on early
endosomes after immunoisolation of these structures
and by immuno-electron microscopy of cryosectioned
w xBHK, MDCK and J774 cells 163,164 ; Diakonova,
M., V. Gerke, J. Ernst, G. van der Vusse, G. Grif-
.fiths, submitted for publication . Interestingly the
submembranous localization of the protein, both at
the level of the plasma membrane and the early
endosomal membrane, is not uniform. This is evident
in polarized cells enterocytes, filter-grown MDCK
.cells, mammary epithelial cells , where annexin II
appears concentrated underneath the apical mem-
w xbrane 74,165–167 , and in J774 macrophages, where
the protein is enriched in plasma membrane areas
showing ruffles, microvilli and membrane folds as
compared to more smoother parts of the membrane
Diakonova, M., V. Gerke, J. Ernst, G. van der
.Vusse, G. Griffiths, submitted for publication . Like-
wise the early endosome-associated annexin II ap-
pears not uniformly distributed over the endosomal
membrane but is concentrated in discrete regions
which in some cases have also filamentous material
w xattached to them 164 . These results are indicative of
a role of annexin II in organizing membranes, possi-
bly by linking certain membrane domains to the
 .underlying cytoskeleton see below . In addition to
the plasma membranerendosome localization an-
nexin II is also present on vesicles of the secretory
transport route, at least in certain types of cells. Such
cell types include adrenal chromaffin cells, where the
protein is a major constituent of the chromaffin gran-
w xules 77,168,169 , and secretory cells of the anterior
pituitary where some annexin II appears to reside on
w xthe secretory granules 170,171 . In quick-freeze,
deep-etch analyses of these secretory cells it even
appears that annexin II can form physical connections
or bridges between the plasma membrane and the
membrane of the respective secretory vesicles
w x169,171 . Finally, annexin II has also been identified
in phagosome preparations from J774 macrophages
w x172 .
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While annexin II appears to serve a structural role
in the cells and systems discussed above its associa-
tion with the different membranes appears to be
regulated by different means. In MDCK cells, for
example, treatment with trifluoperazine or cultivation
in a low-Ca2q medium leads to a translocation of
annexin II from the plasma membrane to the cyto-
w xplasm 173,174 . This could be a direct consequence
of a drop in the intracellular Ca2q levels since Ca2q
binding is a prerequisite for tightly anchoring annexin
w xII in the cortical cytoskeleton of fibroblasts 79 .
Cellular differentiation often represents another stim-
ulus regulating the annexin II association with certain
membranes. Examples are mammary epithelial cells,
which show a striking appearance of annexin II on
the apical, secretory membrane only after parturition,
and cultivated MDCK cells, in which translocation of
cytosolic annexin II to the apical and basolateral
membranes is observed after establishment of a polar-
w xized cell morphology 166,173 . Finally, the stimula-
tion of certain membrane transport events appears to
correlate with the regulated association of annexin II
with specific membranes. This is evident in hepato-
cytes, where the transcytosis of cholestatic bile salts
leads to extensive redistributions of annexin II from
the basolateral membrane to the perinuclear region
w xand finally to the apical membrane 175 and in
nicotine-stimulated chromaffin cells, where cate-
cholamine secretion is accompanied by a transloca-
tion of annexin II from the cytosol to the plasma
w xmembrane 80 . It seems likely that in addition to
changes in the intracellular Ca2q levels other signals
are involved in regulating the annexin II–membrane
interactions. These could include phosphorylation at
one ore more of the sites found in the N-terminal
domain of annexin II since a peptide corresponding
to this N-terminal sequence interferes with the
above-mentioned translocation in nicotine-stimulated
w xchromaffin cells 80 and since phosphorylation by
protein kinase C of Ser-11 of annexin II interferes
w xwith p11 binding 21,176 which itself is prerequisite
for anchoring annexin II tightly in the submembrane-
w xous cytoskeleton 79 .
The subcellular distribution of annexin III has
mainly been studied in neutrophils and
monocytesrmacrophages. Here, the protein is found
on the plasma membrane and on the membranes of
w x intracellular granules and phagosomes 177 Di-
akonova, M., V. Gerke, J. Ernst, G. van der Vusse,
.G. Griffiths, submitted for publication . As also ob-
served for annexin I, a translocation of annexin III to
the phagosomal and the plasma membrane is induced
upon phagocytosis and upon stimulation of the cells
w xwith phorbol ester 159,177 .
Annexin IV, which is most abundantly expressed
in epithelial cells, is found associated with the plasma
membrane although different domains of this mem-
brane appear to be the prime site of annexin IV-as-
sociation in different types of polarized epithelial
cells. In enterocytes and epithelial cells of the lung
annexin IV is enriched on the basolateral plasma
w xmembrane domain 178,179 , whereas the protein has
w xbeen localized to the apical 129 and the basolateral
w xmembrane domain 180 in renal epithelial cells and
to the apical plasma membrane in epithelial cells of
w xthe uterus 181,182 . In addition to the plasma mem-
brane-localized pool some endosome-associated an-
nexin IV has been identified in J774 macrophages
and BHK cells Diakonova, M., V. Gerke, J. Ernst,
G. van der Vusse, G. Griffiths, submitted for publica-
. w xtion 133 .
Annexin V is another member of the family which
has been identified on the plasma membrane and on
w xendocytotic membranes in a variety of cells 183,184
Diakonova, M., V. Gerke, J. Ernst, G. van der
.Vusse, G. Griffiths, submitted for publication . In
certain types of cells some annexin V is also found
associated with the endoplasmic reticulum glial cells,
w x. 185 and the sarcoplasmic reticulum skeletal mus-
w x.cle, 184 . As observed for other annexins certain
stimuli lead to a translocation of cytosolic annexin V
to membranes. In platelets thrombin induces such
relocation resulting in a tight, Ca2q-insensitive asso-
w xciation of annexin V with the membrane 186 and
membrane depolarization has been shown to lead to a
membrane translocation of annexin V in neuroblas-
w xtoma cells 187 . Finally, in human dendritic cells
endocytosis of fluorescently labelled albumin is ac-
companied by a re-distribution of annexin V which
colocalizes with the albumin-containing vesicles
w x188 .
The intracellular localization of annexin VI is
somewhat more controversial. While it has been iden-
tified on the plasma membrane in a variety of cell
w xtypes including lymphocytes 189 and hepatocytes
w x167,190 , a codistribution with mitochondria of liver
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w xcells 191 , the sarcoplasmic reticulum of skeletal
muscle and structures most likely resembling the
w xendoplasmic reticulum of non-muscle cells 192 has
also been observed. The latter can be correlated with
the modulating activity annexin VI exerts on the
2q w x sarcoplasmic Ca release channel in vitro 123 see
.also discussion above . Using subcellular fractiona-
tion annexin VI has also been localized to phago-
w xsomes of J774 macrophages 172 and to endosomal
w xmembranes of rat liver 193 although a specific
endosomal enrichment of annexin VI has not been
w xobserved in BHK cells 62 . Collectively, these data
suggest that annexin VI could act on a variety of
target membranes and that these interactions are regu-
lated differently in different types of cells.
Annexin VII, the protein initially described as the
granule aggregating activity of adrenal chromaffin
 .cells see above , is present in the cytosol of these
cells but appears concentrated around the granule
w xmembrane in the granular cell area 194 . Whereas
the protein is also located in the cytosol of cultured
muscle cells it is found preferentially on the plasma
membrane and on transverse tubules in striated mus-
w xcle 195 .
While only very scarce or no information is avail-
able about the subcellular distribution of annexin VIII
and the Drosophila annexins IX and X, several re-
ports have described the localization of annexin XI.
Interestingly, in cultured fibroblasts this annexin is
localized to the nucleus and this localization depends
on the presence of the long N-terminal domain
w x196,197 . In contrast, a 42-kDa fragment of this
protein appears to be cytosolic protein in neutrophils
which translocates to the membrane of the neutrophil
2q w xgranules in a Ca -dependent manner 198 .
Annexin XIII is the last mammalian identified so
far. It was initially described as an intestinal specific
annexin and was shown to be particularly enriched in
the apical brush border region of different enterocytes
although some annexin XIII was also found associ-
w xated with the basolateral membranes 72 . A splice
variant of this protein containing a 41 amino acid
sequence inserted in the N-terminal domain, annexin
XIIIb, was identified as a component of apical exocy-
totic carrier vesicles purified from polarized MDCK
cells and was specifically localized to these vesicular
structures and the apical plasma membrane of such
w xcells by immunocytochemical techniques 73 . The
mechanisms specifying and regulating these and other
distinct membrane interactions of individual annexins
are not known but are likely to require the unique
N-terminal domains of the molecules and, in the case
of annexin XIIIb, the spliced-in exon.
The examples discussed above stress the impor-
tance of annexin–membrane interactions and this is
supported by the finding that the membranes of es-
sentially all intracellular compartments are stained
with a pan-annexin antibody on cryosections of BHK
w xcells 199 . However, one should keep in mind that
most annexins are not permanently associated with
the respective target membranes. Certain cellular con-
dition, in most cases an elevated Ca2q concentration
appears to be of crucial importance, need to be met
for an annexin to bind to membranes. Thus, annexin
proteins are likely to shuttle between the cytosol and
 .their target membrane s thereby participating in
membrane-related processes in a regulated manner.
The recent documentations of Ca2q-independent an-
nexin–membrane interactions, however, seem to sug-
gest that a non-regulated binding to membranes can
occur in the case of some annexins or certain iso-
forms of individual annexins. Examples are here the
Ca2q-independent associations of myristoylated an-
w xnexin XIIIb with apical transport vesicles 73 , of
annexin II with certain domains of the early endoso-
w xmal and the plasma membranes 133,164 and of
non-phosphorylated annexin I with multivesicular
w xbodies 69 .
A striking example for the membrane localization
of annexins has recently also been provided in the
case of a lower eucaryotic species, the nematode
Caenorhabditis elegans. Here, the product of the
nex-1 annexin gene is present in high concentrations
on membrane systems in the spermathecal valve.
These membranes unfold and then refold in an ac-
cordeon-like fashion as eggs pass through the valve,
suggesting that the nex-1 annexin could participate in
mediating this type of membrane–membrane interac-
w xtions 200 .
5.2. Annexins in exocytosis
The first annexin described in the literature, an-
nexin VII, was purified as a component capable of
aggregating chromaffin granules in a Ca2q-dependent
manner and ever since annexins have been implicated
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in exocytotic events, in particular in the Ca2q-regu-
 w x.lated secretion for review see 2 . Although direct in
vivo data for such a role of annexins are still not
available, some interesting approaches in the recent
years have provided further evidence for the involve-
ment of annexins in transport along the biosynthetic
pathway, in particular in late exocytotic steps occur-
ring at or close to the plasma membrane.
Annexin I, for example, was implicated in the
glucose-induced insulin secretion in rat pancreatic
islets since it specifically locates to insulin-containing
granules during this process. Interestingly, the secre-
tion process correlates with a phosphorylation of
 .  . w xannexin I on a serine residue s 162 . A function of
annexin I in exocytotic events is also in line with the
finding that the protein represents a major fusogenic
w xactivity of the cytosol from human neutrophils 201 .
Various studies using adrenal chromaffin cells and
their exocytotic granulae have focused on annexin II
and the annexin II p11 complex as a potential medi-2 2
ator of Ca2q-regulated secretion of the granule con-
tent. Annexin II was identified as a prominent gran-
 w x.ule protein for review see 2 , it was localized to the
w xsite of the granule–plasma membrane contact 169
and was shown to be capable of aggregating isolated
chromaffin granules at Ca2q concentrations occurring
w xwithin the stimulated cells 77 . Furthermore, in per-
meabilized chromaffin cell systems the progressive
loss of secretory responsiveness to Ca2q stimulation
can be slowed down by adding purified annexin II
w x202 . This effect of annexin II depends at least in
part on the annexin II–p11 complex formation since
monomeric annexin II is less efficient in the assay
than the heterotetrameric complex. Moreover, protein
kinase C-catalyzed phosphorylation of annexin II ap-
pears to be required for the stimulatory activity of the
protein, correlating well with the activation of the
enzyme during nicotine stimulation of adrenal chro-
w xmaffin cells 68 . In vitro studies also revealed that
phosphorylation of chromaffin granule-bound an-
nexin II by protein kinase C induced a fusion of the
w xaggregated chromaffin granule membranes 203 . Fi-
nally, a careful analysis of the annexin II localization
in chromaffin cells revealed that monomeric annexin
II translocates from the cytosol to the subplasmalem-
mal region upon nicotinic stimulation of cate-
w x 2qcholamin secretion 80 . This is a Ca -triggered
process which appears to be accompanied by annexin
II–p11 complex formation since p11 is restricted to
the cortical region even of unstimulated cells. How-
ever, apart from the annexin II–p11 interaction other
modes of regulation are likely to be involved in
inducing this translocation since a synthetic annexin
II peptide covering amino acids 15–26, i.e. a region
of the N-terminal domain containing phosphorylation
sites but not the p11 binding site, blocks the
nicotine-induced recruitment of annexin II to the cell
periphery and concomitantly inhibits the Ca2q-tri-
w xggered catecholamine secretion 80 . The proposed
role of annexin II in Ca2q-regulated secretion is most
likely not restricted to adrenal chromaffin cells since
exogenously added annexin II also stimulates the
Ca2q-induced exocytosis of lamellar bodies in perme-
w xabilized alveolar epithelial cells 204 .
Subcellular localization and the use of a permeabi-
lized cell system have also helped to identify another
annexin most likely involved in transport steps along
the exocytotic pathway. Annexin XIIIb, an N-termi-
nal splice variant of the intestine-specific annexin
XIIIa, is found specifically enriched on apical trans-
port vesicles of polarized MDCK cells. Moreover,
antibodies directed against the unique exon in an-
nexin XIIIb, interfere with vesicle transport to the
w xapical but not the basolateral plasma membrane 73 .
This was shown in permeabilized MDCK cells after
the apical and basolateral plasma membranes had
been perforated separately by treatment of sheets of
 .polarized cells with streptolysin O SLO adminis-
tered either from the apical or the basolateral side. In
these cells transport of exocytotic vesicles from the
trans-Golgi network to the apical and the basolateral
 .plasma membrane the one not treated with SLO can
be restored by adding cytosol and ATP, and antibod-
ies to annexin XIIIb had a specific inhibitory effect
on the apical route. Interestingly, the apical vesicle
traffic in this system is not affected by targeting the
SNARE–SNAP–NSF-dependent docking–fusion
machinery through the use of antibodies or bacterial
toxin whereas the basolateral transport is clearly in-
w xhibited by these agents 205 . In contrast, transcytosis
of pre-internalized IgA receptor to the apical surface
of polarized, SLO-permeabilized MDCK cells is sen-
sitive to N-ethylmaleimide and Botulinum neuro-
toxin, indicating that this transport route is SNARE–
w xSNAP–NSF-dependent 206 . These findings indicate
that annexin XIIIb could be part of a certain special-
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ized exocytotic machinery acting independently of
the known NSF, SNAPs and SNAREs. It remains to
be seen whether annexins are also involved directly
or indirectly in other apparently NSF-independent
vesicle transportrfusion pathways, e.g. a certain exo-
w xcytotic route in BHK and hamster CHO cells 207
w xand the homotypic fusion of ER membranes 208 ;
w x.for review see 209 .
Localization studies have also provided circum-
stantial evidence for an involvement of annexins or
annexin-like proteins in exocytotic processes in lower
organisms. In Paramecium, several proteins were
tentatively identified as annexins by immunological
and biochemical criteria. Antibodies recognizing these
proteins revealed a dynamic labelling of cortical
structures during trichocyst exocytosis, suggesting
that annexin-like proteins are involved in the site-
specific positioning and attachment of secretory or-
w xganelles at the surface of Paramecium cells 210 .
One of the annexins of C. elegans, the product of the
so-called nex-1 gene, is specifically associated with
several membrane systems of different cell types of
the adult nematode. Among them are secretory gland
cells of the pharynx, a finding providing further
circumstantial evidence for a possible participation of
annexins in exocytotic events in simple organisms
w x200 .
The mechanistic aspects of the annexin action in
the exocytotic processes discussed above are not
understood. Since the proteins appear not to be fuso-
genic per se an exception could be phosphorylated
.annexin II bound to chromaffin granules, see above
they might need physiologically occurring cofactors,
e.g. cis-unsaturated fatty acids, to exert such activi-
 w x.ties for review see 2 . Alternatively, annexins may
serve a structural role by physically linking secretory
vesicles to one another andror to the plasma mem-
w xbrane 169 . This could hold the vesicle in place for
the actual fusion event to occur. Moreover, certain
annexins might also provide a connection between
the vesicle membrane and cytoskeletal elements
thereby aiding vesicle traffic andror contact with the
plasma membrane. However, a major conceptual
problem with all models discussed concerns the
specificity. Based on the central biochemical activity
displayed by annexins, i.e. the Ca2q-dependent bind-
ing to acidic phospholipids, it is not entirely clear
why individual annexins interact preferentially with a
certain target membrane, e.g. the annexins mentioned
above with that of the exocytotic vesicle or the
plasma membrane. A certain degree of specificity
could stem from the observed preference of a given
annexin for a certain phospholipid headgroup see
.above and the unequal distribution of the different
acidic phospholipids over the different intracellular
membranes. Alternatively, specific membrane pro-
teins or certain subdomains of membrane lipidsrpro-
teins might exist which act as receptors for a unique
domain or structure within a given annexin, e.g. the
alternatively spliced exon in the N-terminal domain
of annexin XIIIb. Some experimental evidence for
the existence and structural basis of such specific
annexin–membrane interactions exists in the case of
annexins I and II and their association with endocy-
 .totic membranes see below .
5.3. Annexins in endocytosis
In addition to the immunocytochemical localiza-
 .tions see above data from in vitro as well as in vivo
approaches have implicated several annexins in trans-
port andror sorting events along the endocytotic
pathway. Annexin I is a major substrate for the EGF
receptor kinase which becomes phosphorylated on
Tyr-20 in the N-terminal domain upon internalization
w xof the receptor 211–213 . Using NIH 3T3 cells
w xoverexpressing the EGF receptor Futter et al. 69
could show that annexin I phosphorylation by the
receptor kinase occurs in multivesicular bodies
 .MVBs , endocytotic compartments involved in sort-
ing receptors destined for degradation such as the
EGF receptor away from recycling receptors which
return to the plasma membrane. In the NIH 3T3 cells
this sorting process, i.e. the removal of EGF recep-
tors to the internal vesicles of the MVBs, correlates
with the tyrosine phosphorylation of annexin I which
somehow alters the mechanism by which annexin I
associates with the MVB membrane. While unphos-
phorylated annexin I appears to interact at least to
some extent with both, the plasma membrane and the
membrane of MVBs, in a Ca2q-independent manner,
phosphorylation by the EGF receptor kinase converts
it to a form requiring Ca2q for membrane interactions
w x69 . Collectively, these findings suggest that phos-
phorylation of annexin I provides a signal for the
sorting of the EGF receptor in the MVBs and that
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phosphorylated annexin I could participate in the
w xinward vesiculation process 69 . However, by sub-
cellular fractionation and immunocytochemical local-
ization on cryosections of BHK and MDCK cells the
bulk of membrane-bound annexin I was identified on
the plasma membrane and on the membrane of early
endosomes but not on that of late and multivesicular
w xendosomes 62 . Moreover, it appears that in this case
the membrane association is strictly dependent on the
presence of micromolar Ca2q concentrations. While
the basis of this discrepancy is not known it seems
reasonable to assume that the cell system used, in
particular the overexpression of the EGF receptor in
the case of the NIH 3T3 cells, could be of impor-
tance. Overexpression of the receptor and the result-
ing increase in internalization could alter to some
extent the intracellular distribution of one of its sub-
strates, annexin I, shifting it from early to multivesic-
ular endosomes.
Subcellular fractionation in combination with the
ectopic expression of mutant annexin I derivatives
also revealed that in BHK cells the specific associa-
tion of this annexin with its target membranes, the
plasma membrane and that of early endosomes, is
mediated through the unique N-terminal domain.
While a truncation of residues 1 to 13, i.e. the region
representing the S100C binding site in annexin I
w x86,87 does not affect the early endosomal associa-
tion of the molecule, a further deletion of an addi-
 .tional 13 residues 13–26 abolishes this co-fractiona-
w xtion 62 . The region of interest in the annexin I
 .molecule residues 13–26 harbours phosphorylation
sites for the EGF receptor kinase and protein kinase
C. However, phosphorylation at these sites appears
not to be directly involved in specifying the early
endosomal membrane interaction as annexin I deriva-
tives with mutated phosphorylation sites continue to
co-fractionate with early endosomes J. Seemann and
.V. Gerke, unpublished observation . The findings
therefore provide evidence for the existence of an
early endosomal receptor protein or certain mem-
.brane-lipid structure which interacts with the region
spanning residues 13–26 in the N-terminal domain of
annexin I. Likewise, it remains possible that this
N-terminal sequence specifically affects the mem-
brane binding properties of annexin I through some
sort of intramolecular communication.
Annexin II is another annexin implicated in early
endocytotic events. It is specifically localized to cer-
tain areas of the plasma membrane and to cisternal
and tubular regions of early endosomes in different
w x types of cells 163,164,173 Diakonova, M., V.
Gerke, J. Ernst, G. van der Vusse, G. Griffiths,
.submitted for publication . Moreover, in vitro sys-
tems reproducing the homotypic fusion between early
endosomal membranes revealed that annexin II is one
of the few proteins transferred efficiently from a
w xdonor to an acceptor endosomal membrane 163 and
that antibodies against annexin II interfere with a
2q w xCa -dependent endosomal fusion event 214 . In
vivo evidence for the participation of this annexin in
endocytosis stems from the transient expression of a
trans-dominant annexin II mutant. This mutant
molecule, in which the N-terminal 18 amino acids of
annexin II are fused to an entire p11 chain, leads to
the formation of annexin IIrp11 aggregates absorb-
ing the entire intracellular annexin II and p11. In
polarized MDCK cells, where the annexin II–p11
complex is restricted to the cell periphery, the mu-
tant-induced annexin IIrp11 aggregation leads to a
parallel translocation of transferrin receptor-positive
early endosomes from the cell periphery to the sites
w xof the annexin IIrp11 aggregates 173 . This indi-
cates that in such polarized cells the annexin II–p11
complex is involved in establishing andror stabiliz-
ing a peripheral localization of early endosomes pos-
sibly by linking endosomal membranes to the cortical
cytoskeleton.
It remains to be seen whether such a structural role
of the annexin II–p11 complex is regulated by Ca2q,
in particular since annexin II can interact with endo-
somal membranes in a Ca2q-independent manner.
This was revealed by subcellular fractionation of
BHK cell membranes in the presence of a Ca2q-
chelating agent and subsequent analysis of the an-
nexin II content in the early endosomal fraction
w x133,164 . Moreover, an ectopically expressed an-
nexin II mutant with inactivated type II Ca2q binding
sites continues to co-fractionate with early endosomal
w xmembranes 133 . Interestingly, the endosomal asso-
ciation is not affected by deleting the p11 binding
 .domain of the molecule residues 1–14 but is sensi-
tive to a deletion of residues 14–26 in N-terminal
w xdomain of annexin II 133 . This supports the idea of
 .a membrane receptor lipid or protein which is pre-
sent on early endosomes and interacts in a Ca2q-inde-
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pendent manner with a unique sequence in the an-
nexin II molecule.
A Ca2q-independent association of annexin VI
with cellular membranes isolated from BHK cells has
also been observed although a specific enrichment on
individual compartments is not evident in this case
w x62 . This contrasts the situation in rat liver cells
where annexin VI specifically co-fractionates with
w xearly endosomes 193 . An in vitro assay measuring
the loss of clathrin from immobilized plasma mem-
branes has directly implicated this annexin in coated
 .pit budding. The budding s loss of clathrin was
dependent on cytosol, Ca2q and ATP, was inhibited
when annexin VI-depleted cytosol was used and was
restored upon supplementing the depleted cytosol
w xwith purified annexin VI 215 . The view that an-
nexin VI has a general role in the coated vesicle
formation during receptor mediated endocytosis has,
however, been challenged by the finding that the
protein is not expressed in every cell type carrying
out receptor-mediated endocytosis. This is the case in
human A431 cells which do not express annexin VI
and where rate and extent of receptor-mediated endo-
cytosis are not affected by ectopically expressing the
w xprotein 216 . Thus, annexin VI either is required for
the clathrin-coated vesicle budding only in certain
cell types or exercises its budding activity only in the
particular in vitro system and not in living cells.
More in vivo information is required to settle this
point in particular and to explain mechanistic aspects
of the annexin functions in exocytosis and endocyto-
sis in general.
5.4. Annexins in membrane organization
The proposed functions of annexins in exocytotic
and endocytotic membrane transport events would be
in accord, at least to a large extent, with a role of the
proteins in organizing and stabilizing certain mem-
brane domains. Such membrane organization would
be required for cytoskeletal attachment and lipid seg-
regation and would in turn affect vesicular transport
from a donor to an acceptor compartment. At the
level of the plasma membrane, for example, domain
organization reflects itself in coated pits, where mem-
brane receptors destined for internalization are con-
centrated, and in cholesterol-rich membrane rafts,
 .where certain lipids e.g. glycosphingolipids and
 .proteins e.g. caveolin, GPI anchored proteins, CD44
 w x.are enriched for review see 217,218 . Likewise, a
membrane organization is probably required in the
early endosomal compartment, e.g. to separate
molecules destined for transport to late endosomes
from those recycling back to the plasma membrane
 w x.for review see 219 , and in the trans-Golgi network
where a sorting of vesicles carrying material to dif-
ferent plasma membrane domains and to lysosomes
 w x.occurs for review see 220,221 .
Several structural components localized at the cy-
tosolic faces or in the cytosolic leaflets of the respec-
tive membranes are known to be involved in generat-
ing andror stabilizing membrane domains. These
include adaptor molecules of the respective vesicle
coats, e.g. AP1 and AP2 complexes of clathrin coats,
and the cholesterol binding protein VIP 21rcaveolin.
However, less is known about a possible linkage of
these or other membrane structuresrdomains to the
submembraneous, actin-dominated cytoskeleton.
Based on their biochemical properties and their dis-
crete localization to certain membrane domains, e.g.
of the plasma membrane of macrophages Di-
akonova, M., V. Gerke, J. Ernst, G. van der Vusse,
.G. Griffiths, submitted for publication , it remains
possible that some annexins participate in anchoring
certain membrane domains at the cortical cyto-
skeleton or in establishing a certain lipid segregation
per se.
Experimental evidence for such models is several-
fold. Due to the preferential, Ca2q-bridged interaction
of annexins with phospholipids containing negatively
charged headgroups a binding of the proteins could
induce a clustering of such acidic phospholipids in
the plane of the cytosolic leaflet of the membrane. In
the case of annexin IV, for example, binding to
mixed lipid membranes containing phosphatidylglyc-
erol and phosphatidylcholine induces a segregation of
w xthe lipids 222 . The annexin II–p11 complex, a
prominent component of the cortical cytoskeleton of
many cells, has long been implicated in providing a
membrane–cytoskeleton contacts for review see
w x.64 . Recently, cholesterol-rich membrane domains
have been identified as a discrete site for annexin II
attachment. Moreover, cholesterol-clustering agents,
like filipin and digitonin, selectively release from
membrane fractions containing an EGTA-resistant
form of annexin II a limited set of proteins, namely
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annexin II itself, actin and the actin binding proteins
w xa-actinin, ezrin and moesin 164 . Since these com-
ponents from a multiprotein complex in the presence
of cholesterol-containing membranes it appears that
annexin II could participate in specifically linking
cholesterol-rich membrane domains to the actin cyto-
w xskeleton 164 . Such a structural role of annexin II
might also be the mechanistic basis of the proposed
function of the annexin II–p11 complex in sensing or
transmitting mechanical signals. In endothelial cells,
the mechanical activation through shear stress or cell
.volume changes of a chloride channel in the plasma
membrane is sensitive to disrupting the annexin II–
p11 complex. This has been shown by an electro-
physiological analysis of cells loaded via the patch
pipette with a peptide comprising the N-terminal 14
residues of annexin II. This peptide harbours the
entire p11 binding site and efficiently interferes with
w xannexin II–p11 complex formation 81 . The
peptide-induced disruption of the annexin II–p11
complex leads to a significant decrease in the ampli-
tude of the volume-activated chloride current. More-
over this effect is highly specific since a mutant
peptide, which contains a single amino acid replace-
ment resulting in a more than 1000 times reduced
w xaffinity towards p11, has no effect 223 . As depicted
schematically in Fig. 3, these data suggest that the
annexin II–p11 complex could be involved in stabi-
lizing certain membrane domains those having a
.high cholesterol content through a complexation with
the underlying cytoskeleton and that this organization
is required to provide the structural rigidity necessary
Fig. 3. Putative role of the annexin II–p11 complex in organizing membrane domains. The schematic illustration depicts a lipid bilayer
 .containing different domains black and cross-hatched linked at certain points to an underlying cortical cytoskeleton. This organization
leads to a restricted diffusion and thus a segregation of certain membrane lipids and proteins resulting, e.g., in a different membrane
composition of buds forming at a donor membrane. A putative protein complex connecting membrane domains to the cortical
cytoskeleton is shown enlarged. It contains annexin IIrp11 together with one or more additional actin-binding proteins and a membrane
 .receptor specifically interacting with cholesterol-rich membrane domains see text for discussion . Such a structure depends on the
w xformation of the heterotetrameric annexin II–p11 complex which itself can be regulated by phosphorylation 176 . Disruption the annexin
II–p11 complex with a specific p11 binding peptide could therefore lead to some uncoupling of membrane–cytoskeleton contacts
w xresulting, e.g., in a reduced cellular response to mechanical shear stress activation 223 .
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for sensing mechanical alterations at the level of the
plasma membrane.
6. Conclusions and outlook
Due to their thoroughly studied biochemical prop-
erties annexins have long been known as Ca2q-regu-
lated phospholipid and membrane binding proteins.
Nevertheless it has not been and to a large extent
.still is not clear how these well established proper-
ties translate into and correlate with the physiological
roles of these proteins. Moreover, it has been enig-
matic for a long time why such a complex multigene
family has evolved with their individual members
showing strikingly similar biochemical properties.
The recent findings discussed in this review con-
tribute to our understanding towards this end. Struc-
tural work, detailed intracellular localizations and
functional attempts using permeabilized cell systems
and the overexpression of annexin mutant proteins
provide increasing evidence that annexins indeed
function in membrane related events. These ap-
proaches also reveal that different annexins act on
different target membranes and most likely display
different biological activities thus explaining the need
for a complex multigene family. The general theme
emerging is that the two structurally defined domains
of an annexin, the C-terminal protein core and the
N-terminal tail, are designed to perform different
functions. The conserved protein core is a building
block mediating Ca2q-regulated membrane associa-
tion and the highly divergent N-terminal domain is an
entity specifying membrane contact and modulating
the activity of a membrane bound annexin core, e.g.
through the interaction with specific protein ligands.
The latter most likely involves the establishment of
membrane–membrane and membrane–cytoskeleton
interactions and the organization of membrane do-
mains, activities required for membrane sorting and
vesicle traffic along the exocytotic and the endocy-
totic routes. Possibly, target membrane selection and
intra- as well as intermolecular regulation could also
specify that a certain annexin once docked at the
appropriate membrane can also affect ion currents
across this membrane. Future in vivo work, e.g.
annexin gene knock outs in cell lines and in animals
which are currently under way, have to settle these
points and have to establish the mechanistic basis for
the function of annexins in membrane dynamics.
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